Now we intend to evaluate safety, tolerability and preliminary antitumor activity of KO-2806 in a Phase 1 dose escalation study, which we're calling FIT-001.

Source: https://seekingalpha.com/article/4602862-kura-oncology-inc-kura-q1-2023-earnings-call-transcript?source=feed_all_articles

The results demonstrate that olverembatinib and Bcl-2 inhibitor lisaftoclax have synergistic antitumor effects in imatinib-resistant GIST.

Source: https://www.prnewswire.com/news-releases/aacr-2023--ascentage-pharma-presents-results-from-three-studies-underscoring-exploratory-efforts-in-potential-new-indications-301799608.html

This multi-center, open-label trial is intended to evaluate the safety, tolerability, pharmacokinetics antitumor activity and pharmacodynamics of 154 in combination with liposomal doxorubicin.

Source: https://seekingalpha.com/article/4582238-shattuck-labs-inc-sttk-q4-2022-earnings-call-transcript?source=feed_all_articles